Considering quantity and quality of life in metastatic castration-naive prostate cancer

Affiliations

¹ Department of Urologic Surgery Health Policy and Medicine and Center for Surgical Quality and Outcomes Research, Vanderbilt University Medical Center, Nashville, TN 37232, USA; VA Tennessee Valley Geriatric Research, Education, and Clinical Center (GRECC), Nashville, TN, USA. Electronic address: david.penson@vanderbilt.edu.

Comment

David F Penson. Lancet Oncol. 2018 Feb.

. 2018 Feb;19(2):153-154.

doi: 10.1016/S1470-2045(17)30908-7. Epub 2018 Jan 8.

¹ Department of Urologic Surgery Health Policy and Medicine and Center for Surgical Quality and Outcomes Research, Vanderbilt University Medical Center, Nashville, TN 37232, USA; VA Tennessee Valley Geriatric Research, Education, and Clinical Center (GRECC), Nashville, TN, USA. Electronic address: david.penson@vanderbilt.edu.

No abstract available

Comment on

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K. Chi KN, et al. Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8. Lancet Oncol. 2018. PMID: 29326030 Clinical Trial.